2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Abstract Number: 2670

Work Disability in Newly Diagnosed Patients with Primary SjöGren’s Syndrome – a Population-Based Cohort Study
Abstract Number: 2671

Impaired Bone Health in Patients with Primary Sjogren’s Syndrome
Abstract Number: 2672

Elderly Patients Risk a False Positive Diagnosis of Primary Sjogren’s Syndrome If a Positive Labial Gland Biopsy Is Solely Based on Focus Score
Abstract Number: 2673

Glandular Ultrasonography in Primary SjöGren Syndrome: Clinical and Laboratory Correlation
Abstract Number: 2674

Primary Sjögren’s Syndrome: Extraglandular Manifestations and Hydroxychloroquine Therapy
Abstract Number: 2675

Essdai, Clinessdai and DAS Scoring at Diagnosis of Primary Sjogren Syndrome: Association with the Development of Hematologic and Solid Neoplasias in 1301 Patients
Abstract Number: 2676

Changes in Salivary Gland Echostructure in Patients with Primary SjöGren’s Syndrome over the Time: A Four-Year Longitudinal Study
Abstract Number: 2677

Clinical Features of Primary Sjogren’s Syndrome Associated Lung Involvement with Extro-Glandular Manifestations at Onset
Abstract Number: 2678

EULAR Primary SjöGren’s Syndrome Disease Activity Index (ESSDAI), Results from the National Registry of the Spanish Society of Rheumatology (SJÖGRENSER)
Abstract Number: 2679

Clinically Meaningful Improvement of Essdai and Esspri in Patients with Primary SjöGren’s Syndrome in Real Life: A 12-Month Longitudinal Study
Abstract Number: 2680

Determinants of Fatigue in Patients with Primary SjöGren’s Syndrome and Impact of Fatigue on Patients’ Treatments: A Cohort Study
Abstract Number: 2681

Clinical and Immunological Characteristics of Primary Sjogren´s Syndrome in Men
Abstract Number: 2682

How Does Primary Sjogren Syndrome Present in Biopsy-Proven Patients without Circulating Ro/La Autoantibodies? Characteristics at Diagnosis of 2073 Patients from the SjöGren Big Data Project
Abstract Number: 2683

Isolated Anti-La/SS-B Positivity in Patients Diagnosed with Primary Sjogren Syndrome: Analysis of 222 Patients from the Sjogren Big Data Cohort
Abstract Number: 2684

Diagnosis of Systemic Diseases in Patients Presenting with Sicca Syndrome Using a Minimally-Invasive Minor Salivary Gland Biopsy: Analysis of 901 Patients

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].